Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck

 Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck

Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck

Shots:

  • AstraZeneca & Merck will utilize Myriads’ BRAC Analysis CDx to identify germline BRCA mutations in men who have mCRPC cancer, enrolled in Phase III PROfound (NCT02987543) study
  • In 2007, Myriad collaborates with AZ for BRAC Analysis CDx to be used as a companion diagnostic to Lynparza (olaparib) and the combination has received approval from MHLW & FDA for different indications in oncology
  • Myriad’s BRACAnalysis CDx is an in vitro diagnostic used for detection of germline BRCA1 and BRCA2 variant and provide a clinical interpretation of the identified variants. Myriad plans to file sPMA to FDA for BRACAnalysis CDx used as a companion diagnostic to Lynparza (olaparib) in mCRPC patients

Click here to read full press release/ article | Ref: Myriad | Image: Specialty Pharma Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post